胆囊癌的临床病理及分子研究进展
Clinicopathological and Molecular Insights into Gallbladder Cancer.
作者信息
de Reuver Philip R, van der Post Rachel S
机构信息
Department of Surgery, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands.
Department of Pathology, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands.
出版信息
Cancers (Basel). 2023 May 12;15(10):2728. doi: 10.3390/cancers15102728.
Abstract
Although gallbladder cancer (GBC) is rare, it is one of the few cancers with a higher mortality rate than incidence, accounting for 1 [...].
摘要
尽管胆囊癌（GBC）较为罕见，但它是少数死亡率高于发病率的癌症之一，占1 [...].
相似文献
1
Clinicopathological and Molecular Insights into Gallbladder Cancer.胆囊癌的临床病理及分子研究进展
Cancers (Basel). 2023 May 12;15(10):2728. doi: 10.3390/cancers15102728.
2
Clinicopathological features and CCT2 and PDIA2 expression in gallbladder squamous/adenosquamous carcinoma and gallbladder adenocarcinoma.胆囊鳞癌/腺鳞癌及胆囊腺癌的临床病理特征与CCT2和PDIA2表达
World J Surg Oncol. 2013 Jun 19;11:143. doi: 10.1186/1477-7819-11-143.
3
The ERK/MAPK pathway is overexpressed and activated in gallbladder cancer.ERK/MAPK通路在胆囊癌中过表达并被激活。
Pathol Res Pract. 2017 May;213(5):476-482. doi: 10.1016/j.prp.2017.01.025. Epub 2017 Feb 24.
4
XRCC1 Is a Promising Predictive Biomarker and Facilitates Chemo-Resistance in Gallbladder Cancer.XRCC1是一种有前景的预测性生物标志物，并促进胆囊癌的化疗耐药性。
Front Mol Biosci. 2020 Apr 24;7:70. doi: 10.3389/fmolb.2020.00070. eCollection 2020.
5
Gallbladder cancer-associated fibroblasts promote vasculogenic mimicry formation and tumor growth in gallbladder cancer via upregulating the expression of NOX4, a poor prognosis factor, through IL-6-JAK-STAT3 signal pathway.胆囊癌相关成纤维细胞通过 IL-6-JAK-STAT3 信号通路上调 NOX4 的表达，促进胆囊癌中血管生成拟态的形成和肿瘤生长，NOX4 是一个预后不良的因素。
J Exp Clin Cancer Res. 2020 Nov 5;39(1):234. doi: 10.1186/s13046-020-01742-4.
6
Epigenetic profiling of gallbladder cancer and gall stone diseases: Evaluation of role of tumour associated genes.胆囊癌和胆石病的表观遗传学分析：肿瘤相关基因作用的评估。
Gene. 2016 Feb 1;576(2 Pt 2):743-52. doi: 10.1016/j.gene.2015.10.004. Epub 2015 Oct 8.
7
Prognostic and Clinicopathological Significance of X-Box-Binding Protein 1 and N-Acetyltransferase 1 in Gallbladder Cancer.X盒结合蛋白1和N-乙酰转移酶1在胆囊癌中的预后及临床病理意义
Front Oncol. 2020 Jul 24;10:1124. doi: 10.3389/fonc.2020.01124. eCollection 2020.
8
Bmi-1 in gallbladder carcinoma: Clinicopathology and mechanism of regulation of human gallbladder carcinoma proliferation.Bmi-1在胆囊癌中的作用：人类胆囊癌增殖的临床病理学及调控机制
Oncol Lett. 2019 Aug;18(2):1365-1371. doi: 10.3892/ol.2019.10408. Epub 2019 May 28.
9
Low Expression of MicroRNA335-5p Is Associated with Malignant Behavior of Gallbladder Cancer: A Clinicopathological Study.MicroRNA335 - 5p低表达与胆囊癌恶性行为相关：一项临床病理研究
Asian Pac J Cancer Prev. 2019 Jun 1;20(6):1895-1900. doi: 10.31557/APJCP.2019.20.6.1895.
10
Epidemiological Study of Gallbladder Cancer Patients from North Indian Gangetic Planes--a High-Volume Centre's Experience.印度北部恒河平原胆囊癌患者的流行病学研究——一家大型中心的经验
J Gastrointest Cancer. 2016 Mar;47(1):27-35. doi: 10.1007/s12029-015-9781-5.
引用本文的文献
1
Endoscopic diagnosis and management of gallbladder carcinoma in minimally invasive era: New needs, new models.微创时代胆囊癌的内镜诊断与管理：新需求，新模式。
World J Gastrointest Oncol. 2024 Nov 15;16(11):4333-4337. doi: 10.4251/wjgo.v16.i11.4333.
2
New trends in diagnosis and management of gallbladder carcinoma.胆囊癌诊断与治疗的新趋势
World J Gastrointest Oncol. 2024 Jan 15;16(1):13-29. doi: 10.4251/wjgo.v16.i1.13.
本文引用的文献
1
Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions.胆囊癌：当前的多模态治疗理念与未来方向
Cancers (Basel). 2022 Nov 14;14(22):5580. doi: 10.3390/cancers14225580.
2
Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients.胆囊癌的综合临床病理和基因组分析揭示了半数患者的可靶向治疗靶点。
NPJ Precis Oncol. 2022 Nov 5;6(1):83. doi: 10.1038/s41698-022-00327-y.
3
Palliation in Gallbladder Cancer: The Role of Gastrointestinal Endoscopy.胆囊癌的姑息治疗：胃肠内镜检查的作用
Cancers (Basel). 2022 Mar 26;14(7):1686. doi: 10.3390/cancers14071686.
4
Treatment of Resectable Gallbladder Cancer.可切除胆囊癌的治疗
Cancers (Basel). 2022 Mar 10;14(6):1413. doi: 10.3390/cancers14061413.
5
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.吉西他滨和顺铂联合度伐利尤单抗（无论是否联合曲美木单抗）用于既往未接受过化疗的晚期胆管癌患者：一项开放标签、单中心、2期研究。
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):522-532. doi: 10.1016/S2468-1253(22)00043-7. Epub 2022 Mar 9.
6
Evolving Paradigms in the Systemic Treatment of Advanced Gallbladder Cancer: Updates in Year 2022.晚期胆囊癌系统治疗的发展范式：2022年更新
Cancers (Basel). 2022 Feb 28;14(5):1249. doi: 10.3390/cancers14051249.
7
Neoadjuvant therapy trials in biliary tract malignancies.胆道恶性肿瘤的新辅助治疗试验
J Surg Oncol. 2022 Jan;125(1):84-88. doi: 10.1002/jso.26714.
8
Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications.胆囊癌：基因改变的当前见解及其可能的治疗意义
Cancers (Basel). 2021 Oct 20;13(21):5257. doi: 10.3390/cancers13215257.
9
Quality Assessment of Gallbladder Cancer Pathology Reports: A Dutch Nationwide Study.胆囊癌病理报告的质量评估：一项荷兰全国性研究。
Cancers (Basel). 2021 Jun 14;13(12):2977. doi: 10.3390/cancers13122977.
10
Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease.偶然胆囊癌再次切除术：生存和残留疾病的发生率。
Ann Surg Oncol. 2020 Apr;27(4):1132-1142. doi: 10.1245/s10434-019-08074-4. Epub 2019 Nov 18.
Zotero 插件